Rezolute, Inc.
RZLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001509261
No open-market purchases or sales by Rezolute, Inc. insiders were filed in the last 90 days; 144 institutions reported holding it in 13F filings for Q2 2026, worth $450.3M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Rezolute, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 116
- +24 vs. Q2 2025
- Shares held
- 86.9M
- +9.01M (+11.6%) vs. Q2 2025
- Total value
- $817.1M
- +$469.6M (+135.1%) vs. Q2 2025
- New holders
- 35
- 40 more added
- Sold out
- 11
- 28 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RZLT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 144 | $450.3M |
| Q1 2026 | 125 | $263.2M |
| Q4 2025 | 122 | $213.4M |
| Q3 2025 | 116 | $817.1M |
| Q2 2025 | 92 | $347.5M |
| Q1 2025 | 77 | $130.6M |
| Q4 2024 | 71 | $211.7M |
| Q3 2024 | 59 | $186.9M |
| Q2 2024 | 52 | $170.0M |
| Q1 2024 | 33 | $69.0M |
| Q4 2023 | 32 | $28.7M |
| Q3 2023 | 30 | $31.5M |
| Q2 2023 | 29 | $48.0M |
| Q1 2023 | 32 | $46.5M |
| Q4 2022 | 34 | $50.6M |
| Q3 2022 | 33 | $67.0M |
| Q2 2022 | 35 | $79.2M |
| Q1 2022 | 21 | $24.0M |
| Q4 2021 | 23 | $36.0M |
| Q3 2021 | 14 | $17.6M |
| Q2 2021 | 12 | $31.6M |
| Q1 2021 | 11 | $17.5M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Rezolute, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 1,847,384 | $17.4M | 0.00% | +136,341+8.0% | Added |
| Caxton Corp | 1,986,818 | $18.7M | 81.70% | +382,832+23.9% | Added |
| Integral Health Asset Management, LLC | 2,000,000 | $18.8M | 1.37% | +200,000+11.1% | Added |
| State Street Corp | 2,091,476 | $19.7M | 0.00% | +1,261,402+152.0% | Added |
| Affinity Asset Advisors, LLC | 2,100,000 | $19.7M | 1.84% | −100,000−4.5% | Reduced |
| Vivo Capital, LLC | 2,112,432 | $19.9M | 1.60% | 00.0% | Unchanged |
| Great Point Partners LLC | 2,451,809 | $23.0M | 9.62% | −581,653−19.2% | Reduced |
| UBS Group AG | 2,695,978 | $25.3M | 0.00% | −341,190−11.2% | Reduced |
| Marshall Wace, LLP | 2,728,315 | $25.6M | 0.03% | −158,166−5.5% | Reduced |
| Mangrove Partners | 2,882,149 | $27.1M | 2.25% | +584,660+25.4% | Added |
| Blackstone Group Inc. | 3,023,899 | $28.4M | 0.12% | −536,390−15.1% | Reduced |
| Vanguard Group Inc | 4,410,082 | $41.5M | 0.00% | +387,502+9.6% | Added |
| Siren, L.L.C. | 4,870,000 | $45.8M | 1.79% | +4,870,000 | New |
| BlackRock, Inc. | 5,004,436 | $47.0M | 0.00% | +922,911+22.6% | Added |
| FMR LLC | 12,764,233 | $120.0M | 0.01% | −47,643−0.4% | Reduced |
| Federated Hermes, Inc. | 14,034,712 | $131.9M | 0.23% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 0 | $0 | 0.00% | −2,291,395−100.0% | Sold out |
| Caligan Partners LP | 0 | $0 | 0.00% | −1,543,014−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −455,701−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −266,671−100.0% | Sold out |
| Paloma Partners Management Co | 0 | $0 | 0.00% | −124,994−100.0% | Sold out |
| Allostery Investments LP | 0 | $0 | 0.00% | −119,294−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −52,833−100.0% | Sold out |
| Quadrature Capital Ltd | 0 | $0 | 0.00% | −24,504−100.0% | Sold out |
| Retireful, LLC | 0 | $0 | 0.00% | −15,702−100.0% | Sold out |
| American Century Companies Inc | 0 | $0 | 0.00% | −12,859−100.0% | Sold out |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −10,350−100.0% | Sold out |